Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis

• Status: Unknown status
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Adult cystic fibrosis (CF) patients admitted with an acute infection complicated by acid-base disturbance and decreased ventilation will be studied.

They will receive salt replacement to correct the acid-base disturbance and possibly their ventilation.

Assessment of symptoms (questionnaire), acid-base and electrolyte status (blood and urine tests) ventilation (overnight oxygen and carbon dioxide monitoring non-invasively) and sleep-wake pattern (actigraphy) will be carried out.

Study hypothesis: Acute volume and electrolyte replacement corrects hypochloremic hypovolemic metabolic alkalosis and compensatory hypoventilation/ hypercapnia in acute exacerbations of cystic fibrosis.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bayside Health
• Collaborators: Cystic Fibrosis Federation Australia; Monash University; National Health and Medical Research Council, Australia

Criteria

Inclusion Criteria:

• Adult cystic fibrosis patient

• Admission with acute exacerbation (criteria- fall in FEV1 > 10% from best in last 12/12, change in sputum volume and colour, new pulmonary infiltrate)

• PaCO2 > 45 mmHg on admission

• Primary metabolic alkalosis (acid-base diagram of Stinebaugh and Austin)

• Serum chloride (Cl) ≤ 98 mmol/L

• Serum albumin (alb) ≤ 25 mmol/L

Exclusion Criteria:

Concurrent diuretic therapy Concurrent glucocorticoid therapy